BioSpace News Archive

MustGrow’s safe and effective natural, organic biofumigant, biopesticide and bioherbicide are plant-based - harnessing the mustard seed’s natural defense mechanism to control diseases, insect pests and weeds.

“Ms. D’Angelo joins our team at an important point in the company’s history,” said Michael McFadden, Chief Executive Officer of Alpha Cognition.

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of its 250 mg and 500 mg strength generic Erythromycin tablets—a therapeutic equivalent for the reference listed drug (RLD) Erythromycin Tablets from Arbor Pharmaceuticals.

Santen Canada Inc., a subsidiary of Santen Pharmaceutical Co., Ltd., a global company focused exclusively on ophthalmology, announced the approval of PRESERFLOTM MicroShunt by Health Canada.

NJ Biopharmaceuticals LLC, an expert provider of chemistry and biopharmaceutical services specializing in bioconjugation, custom synthesis, flow chemistry, and process development, announced the move of its headquarters from North Brunswick to Princeton, New Jersey.

A new case report, detailed in Annals of Emergency Medicine, is the first known case of a patient with VITT treated with a heparin alternative following the Centers for Disease Control and Prevention guidance.

The Patient Safety Authority has released its 2020 annual report, offering accounts of ingenuity, tenacity, and teamwork amid COVID-19 and key insights to improve patient safety in Pennsylvania and beyond.

-- First quarter net sales of $1.847 billion increased 3.6%, 0.8% on a constant currency basis -- First quarter diluted earnings per share were $0.94; adjusted diluted earnings per share were $1.71 -- Full-year 2021 guidance provided - Company expects 14% to 17% revenue growth on a reported basis and 12.5% to 15.5% on a constant currency basis versus 2020

Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced the appointment of Scott M. Akamine as chief legal officer, effective May 24, 2021.

LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN, a leader in the discovery, development and delivery of novel short interfering ribonucleic acid therapeutics for the treatment of diseases with significant unmet medical need, announced the launch of a new, retro-inspired, online game to raise awareness of the rare blood disorder, thalassemia, ahead of International Thalassemia Day on Saturday May 8th 2021.